Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 11;105(4):1032–1041. doi: 10.3324/haematol.2018.211904

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2020 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 4. — Daratumumab monotherapy in a systemic model of mantle cell lymphoma and follicular lymphoma compared to rituximab. 10×10⁶ Z-138 mantle celle lymphoma (MCL) and WSU-FSCCL follicular lymphoma (FL) cells were intravenously injected in SCID mice (n=10 per group). Treatment (isotype control [IgG1]/ dara-tumumab/ rituximab) started one week after inoculation and went on weekly for four weeks (20/10/10/10 mg/kg), as indicated by the red arrows. Mice were monitored twice weekly for any sign of disease and were euthanized when body weight decreased 15-20%. Survival curves are represented. Statistical differences between groups were assessed by log-rank test. Z-138: Overall significance***P<0.001; Isotype; control vs. daratumumab ***P<0.01; daratumumab vs. rituximab not signficant (ns) P=0.2907. WSU-FSCCL: Overall significance ***P<0.001; isotype control vs. daratumumab ***P≤0.001; daratumumab vs rituximab *P=0.045.